1. Australia Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Somnomed Limited

Somnomed Limited

0.18
EUR
+0.00
(-0.55%)
-0.01EPS
68.41MMarket Cap
Feb 26Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2026 Y
Revenue per Share
0.27
0.38
0.46
0.58
0.58
0.73
0.64
0.67
0.59
0.68
0.79
0.76
0.54
Basic EPS, GAAP
0.01
0.01
0.01
- -
-0.04
-0.1
-0.18
-0.01
-0.01
-0.04
-0.08
-0.1
-0.01
Free Cash Flow per Basic Share
- -
-0.02
-0.02
- -
-0.06
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.16
0.19
0.28
0.42
0.4
0.42
0.23
0.35
0.3
0.26
0.23
0.22
0.22
Tangible Book Value per Share
0.07
0.02
0.14
0.34
0.33
0.34
0.14
0.27
0.22
0.12
0.05
0.12
0.11
Basic Weighted Avg Shares
68
68
75
77
85
88
91
85
106
106
106
121
212
Sales/Revenue/Turnover
18
26
34
44
49
64
59
57
63
73
84
92
115
Operating Margin (%)
1.11
1.22
0.12
0.15
-7.57
-13.94
1.56
-1.64
-1.36
-5.69
-4.87
-9.09
0.85
Depreciation Expense
1
1
1
1
1
2
1
3
4
4
5
6
5
Net Income, GAAP
1
- -
1
- -
-3
-9
-16
-1
-1
-4
-8
-12
-3
Effective Tax Rate (%)
- -
6.74
23.53
86.31
- -
- -
106.49
158.68
- -
- -
- -
- -
- -
Profit Margin (%)
3.18
1.57
1.73
0.37
-6.78
-13.55
-27.91
-1.95
-1.9
-6.11
-9.57
-13.36
-2.31
Working Capital
5
6
14
22
20
20
3
24
18
3
11
19
16
LT Debt
- -
- -
- -
- -
- -
1
- -
8
7
5
21
4
3
Total Equity
12
13
23
35
35
35
20
37
32
28
25
46
47
Return on Invested Capital (%)
- -
2.32
-0.61
0.03
- -
- -
-0.16
1.36
- -
- -
- -
- -
- -
Return on Capital (%)
- -
4.92
3.73
0.92
- -
- -
-51.93
-3.06
- -
- -
- -
- -
- -
Return on Common Equity (%)
5.99
3.4
3.33
0.57
-9.38
-23.13
-56.03
-3.9
-3.45
-14.8
-30.59
-34.77
-5.68

Capital Structure

AUD

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

AUD

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

AUD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
14.21%
10.46%
3.24%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
-171.01%
66.71%
-78.35%
Sales/Revenue/Turnover
13.37%
14.99%
24.97%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
92
2026
- -
- -
115

Semi-annual Earnings Per Share

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
-0.1
2026
- -
- -
-0.01

Semi-annual Dividends Per Share

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2026
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Karen Borg
Full Time Employees
300
Sector
Health technology
Industry
Medical specialties
Address
20 Clarke Street Sydney NSW Australia 2065
IPO Date
Jul 29, 2004
Website
somnomed.com
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
SomnoMed Limited engages in the design, manufacture, and distribution of premium oral appliances and related accessories for the treatment of sleep-related breathing disorders, including obstructive sleep apnea, snoring, and bruxism; its core products comprise the SomnoDent range, encompassing SomnoDent Avant, SomnoDent Classic, SomnoDent Flex, and SomnoDent Fusion mandibular advancement splints featuring proprietary b-flex Comfort Liner technology for enhanced patient comfort and retention; SomnoBrux splints for bruxism protection; SomMorning Repositioner for post-treatment mandibular realignment; SomTabs cleaning tablets; SomGauge bite registration instrument; Dentitrac compliance recorders; and at-home sleep testing under the Sunrise brand, with recent introductions including the FDA-approved Rest Assure compliance monitoring product and Medicare-approved SomnoDent Herbst Advance Elite. The company operates in North America, Europe, and the Asia-Pacific regions across 28 countries, serving sleep physicians, dental clinicians, and managed care providers. Founded in 2004 and headquartered in Crows Nest (Sydney), Australia, SomnoMed manufactures to ISO 13485 standards and digital platforms for precision fit. In fiscal year 2025 (ended June 2025), SomnoMed reports revenue of $111.5 million, up 21.6% year-over-year and exceeding guidance, with EBITDA of $9.2 million versus $0.6 million prior year, positive free cash flow, reduced order backlogs, and a milestone surpassing one million patients treated globally; earlier, in fiscal 2024, it raised gross equity capital of $38.1 million and fully repaid its Australian debt facility to bolster the balance sheet.

Company News

Company News APIChatGPT

  • seekingalpha.com

    SomnoMed Limited (SOMNF) Q4 2026 Earnings Call Transcript

  • seekingalpha.com

    SomnoMed Limited (SOMNF) Q2 2026 Earnings Call Transcript